Have you registered yet? #Bronchiectasis2024 The 4th annual Bronchiectasis Patient Conference will include talks from our Bronchiectasis Patient Advisory Group (PAG) members! Register here: ow.ly/hq4T50QwUjA

The UK has the worst death rate for lung conditions in Europe. Increasing funding for lung research will improve diagnosis and save lives. Here are the steps the government can take to improve the nation’s lung health: bit.ly/3UtpBTj

So sad to learn of the passing of our friend, Kathryn Bevis. I am sorry to see you go, Kathryn. I send you skylarks.

So sad to learn of the death of Kathryn Bevis. I knew her first of all as a kind soul who cheered other poets on, then as my student. Later, I watched her soar and I used her stunning, resonant work in my teaching. Thinking of her family and many friends. xxx

Join us for a free EMBARC webinar on airway clearance and pulmonary rehabilitation 👇🫁 ERS_physios ERS_Assembly9 ACPRC The London ACPRC Hub Love Your Lungs King's Physiotherapy School of Life Course & Population Sciences

New paper from EMBARC Diagnostic delay and access to care in bronchiectasis A survey of 760 patients from 40 countries 40% of patients wait 5 years+ for a diagnosis and 25% wait >10 years from symptom onset led by Dr Arietta Spinou Michal Shteinberg erj.ersjournals.com/content/erj/ea…

Ask us your questions about bronchiectasis, particularly about current and future treatment. We will then answer these questions live in our Bronchiectasis Question Time webinar on 1 July. Find out more: europeanlung.org/en/get-involve… #WorldBronchiectasisDay

Tomorrow is World Bronchiectasis Day! Join us for a special webinar- ask you questions and get answers from real experts on the condition including מיכל שטיינברג Stefano Aliberti Barbara Crossley and many more I'll be behind the scenes answering as many questions as i can!

No better in Australia. Only around a half of patients with bronchiectasis in Europe perform regular airway clearance. Techniques and use of airway clearance management is heterogeneous, suggesting the need for clearer guidelines and stronger evidence. bit.ly/3v2CFGy

Bronchiectasis is a heterogeneous disease. if we want personalised medicine, we need BIOMARKERS to guide treatment Explore the pathophysiology of bronchiectasis by checking out our latest paper from Emma Johnson and Merete Long err.ersjournals.com/content/errev/…

Patient perspective represented by Barbara Crossley and her colleague from Greece European Lung Foundation EMBARC

The Precision Medicine Era of Bronchiectasis 🔓 Open Access 🔗 tinyurl.com/5n8yz8jy

Good evening from #WBConf24! Today we enjoyed meeting with our #bronchiectasis advisory group and hearing bronchiectasis facts presented in a patient-friendly way. Visit our webpage and learn how we promote the voices of people with bronchiectasis: europeanlung.org/en/people-and-…

Its time to shift the paradigm in bronchiectasis Thinking about bronchiectasis as an inflammatory disease means - earlier intervention - focus on non-antibiotic treatments - clinicians and scientists working together - Pipeline of new anti-inflammatory treatments Merete Long

For most of the past 3 decades, bronchiectasis has been treated as an infectious disease. A new Review in The Lancet Respiratory Medicine argues that bronchiectasis is primarily a chronic inflammatory disease and introduces a novel concept of disease activity: hubs.li/Q02FqqBl0

We patients were so pleased to work with Paul and Beatriz on demonstrating Airway Clearance Techniques that make a world of difference to how we manage our bronchiectasis. Patients - get referred to a respiratory physiotherapist, they can help you take control of your life.

Absolutely agree with this, and Prof James Chalmers and Michal Shteinberg are brilliant at patient-friendly communication. We at the European Lung Foundation’s Patient Advisory Group are incredibly grateful for their support.

We did it! More than 1000 participants joined us for the World Bronchiectasis Conference #WBC2024 hosted in Dundee. Incredible breakthroughs for bronchiectasis patients, warm friendship and so many memories. Thank you to everyone who worked so hard to make this possible ❤️❤️❤️

Bronchiectasis is a lung condition you might not have heard of, but it affects more than 200,000 people in the UK and millions around the world. There are no treatments and it remains hard to diagnose, which is why LifeArc and Asthma + Lung UK are working together to change this.

We bronchiectasis patients are over the moon and incredibly grateful for all you have achieved and for what you continue to achieve to make a difference to our lives. We were totally neglected till you came on the scene. We can’t thank you enough.